This is a two-staged study of a single dose of 200 mg of bosutinib given to subjects with
renal impairment and matching healthy volunteers. In Stage 1, only subjects with severe renal
impairment and subjects with normal renal function will be enrolled. Subjects with mild and
moderate renal impairment will be enrolled in Stage 2 if the results from Stage 1 suggest a
substantial difference in PK profiles between subjects with severe renal impairment and
subjects with normal renal function.